Tabula Rasa HealthCare (TRHC) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 24, 2020
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-37888
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5726437
Entity Address, Address Line One	228 Strawbridge Drive, Suite 100
Entity Address, City or Town	Moorestown
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08057
City Area Code	866
Local Phone Number	648 - 2767
Title of 12(b) Security	Common Stock
Trading Symbol	TRHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,960,407
Entity Central Index Key	0001651561
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 38,752	$ 42,478
Restricted cash	3,132	4,103
Accounts receivable, net of allowance of $482 and $386, respectively	36,896	29,123
Inventories	4,103	3,700
Prepaid expenses	4,173	4,299
Other current assets	6,577	10,835
Total current assets	93,633	94,538
Property and equipment, net	15,531	15,798
Operating lease right-of-use assets	22,411	22,100
Software development costs, net	23,422	18,501
Goodwill	150,760	150,760
Intangible assets, net	175,768	189,413
Other assets	1,017	1,281
Total assets	482,542	492,391
Current liabilities:
Current portion of long-term debt and finance leases, net	8	125
Current operating lease liabilities	4,579	4,350
Accounts payable	7,253	8,622
Accrued expenses and other liabilities	26,944	26,906
Total current liabilities	38,784	40,003
Long-term debt and finance leases, net	232,658	226,294
Noncurrent operating lease liabilities	21,011	21,017
Long-term acquisition-related contingent consideration	11,400	10,800
Deferred income tax liability	4,781	8,656
Other long-term liabilities	485	73
Total liabilities	309,119	306,843
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019
Common stock, $0.0001 par value; 100,000,000 shares authorized, 23,159,311 and 22,496,999 shares issued and 22,955,263 and 22,321,310 shares outstanding at June 30, 2020 and December 31, 2019, respectively	2	2
Treasury stock, at cost; 204,048 and 175,689 shares at June 30, 2020 and December 31, 2019, respectively	(3,956)	(3,865)
Additional paid-in capital	305,058	288,345
Accumulated deficit	(127,681)	(98,934)
Total stockholders' equity	173,423	185,548
Total liabilities and stockholders' equity	$ 482,542	$ 492,391

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CONSOLIDATED BALANCE SHEETS
Allowance for accounts receivable	$ 482	$ 386
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	23,159,311	22,496,999
Common stock, shares outstanding	22,955,263	22,321,310
Treasury stock (in shares)	204,048	175,689

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 76,834	$ 76,255	$ 149,661	$ 137,214
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	51,698	45,156	99,771	86,824
Operating expenses:
Research and development	3,821	5,197	8,649	10,747
Sales and marketing	5,027	6,871	10,567	11,721
General and administrative	16,327	12,883	33,294	26,626
Change in fair value of acquisition-related contingent consideration (income) expense	(100)	1,830	600	3,006
Depreciation and amortization	10,211	9,078	20,124	15,377
Total operating expenses	35,286	35,859	73,234	67,477
Loss from operations	(10,150)	(4,760)	(23,344)	(17,087)
Interest expense, net	4,668	4,308	9,278	7,001
Loss before income taxes	(14,818)	(9,068)	(32,622)	(24,088)
Income tax benefit	(508)	(2,539)	(3,875)	(6,580)
Net loss	$ (14,310)	$ (6,529)	$ (28,747)	$ (17,508)
Net loss per share, basic and diluted (in dollars per share)	$ (0.66)	$ (0.32)	$ (1.34)	$ (0.86)
Weighted average common shares outstanding, basic and diluted (in shares)	21,556,646	20,482,032	21,465,772	20,433,564
Product
Revenue:
Total revenue	$ 39,373	$ 33,372	$ 76,460	$ 64,354
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	29,042	24,861	56,241	48,336
Service
Revenue:
Total revenue	37,461	42,883	73,201	72,860
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	$ 22,656	$ 20,295	$ 43,530	$ 38,488

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2018	$ 2	$ (3,825)	$ 209,330	$ (66,498)	$ 139,009
Balance at beginning of period (in shares) at Dec. 31, 2018	20,719,297	(161,760)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with acquisition			9,504		9,504
Issuance of common stock in connection with acquisition (in shares)	149,053
Issuance of common stock awards (in shares)	9,547
Issuance of restricted stock (in shares)	565,840
Exercise of stock options		$ (40)	1,077		1,037
Exercise of stock options (in shares)	82,686	(690)
Issuance of common stock in connection with the settlement of acquisition-related contingent consideration			(609)		(609)
Issuance of common stock in connection with the settlement of acquisition-related contingent consideration (in shares)	614,225
Conversion feature of convertible senior subordinated notes, net of allocated debt issuance costs, net of tax effect			74,049		74,049
Purchase of convertible note hedges			(101,660)		(101,660)
Sale of warrants in connection with convertible senior subordinated notes			65,910		65,910
Stock-based compensation expense			6,852		6,852
Net loss				(10,979)	(10,979)
Balance at end of period at Mar. 31, 2019	$ 2	$ (3,865)	264,453	(77,477)	183,113
Balance at end of period (in shares) at Mar. 31, 2019	22,140,648	(162,450)
Balance at beginning of period at Dec. 31, 2018	$ 2	$ (3,825)	209,330	(66,498)	139,009
Balance at beginning of period (in shares) at Dec. 31, 2018	20,719,297	(161,760)
Increase (Decrease) in Stockholders' Equity
Net loss					(17,508)
Balance at end of period at Jun. 30, 2019	$ 2	$ (3,865)	271,811	(84,006)	183,942
Balance at end of period (in shares) at Jun. 30, 2019	22,244,227	(162,450)
Balance at beginning of period at Mar. 31, 2019	$ 2	$ (3,865)	264,453	(77,477)	183,113
Balance at beginning of period (in shares) at Mar. 31, 2019	22,140,648	(162,450)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	30,101
Issuance of restricted stock (in shares)	23,562
Exercise of stock options			499		499
Exercise of stock options (in shares)	49,916
Conversion feature of convertible senior subordinated notes, net of allocated debt issuance costs, net of tax effect			(47)		(47)
Stock-based compensation expense			6,906		6,906
Net loss				(6,529)	(6,529)
Balance at end of period at Jun. 30, 2019	$ 2	$ (3,865)	271,811	(84,006)	183,942
Balance at end of period (in shares) at Jun. 30, 2019	22,244,227	(162,450)
Balance at beginning of period at Dec. 31, 2019	$ 2	$ (3,865)	288,345	(98,934)	185,548
Balance at beginning of period (in shares) at Dec. 31, 2019	22,496,999	(175,689)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	14,386
Issuance of restricted stock (in shares)	388,108
Forfeitures of restricted shares (in shares)		(33,371)
Exercise of stock options		$ (91)	1,244		1,153
Exercise of stock options (in shares)	116,288	(1,681)
Share adjustment		12,500
Stock-based compensation expense			7,137		7,137
Net loss				(14,437)	(14,437)
Balance at end of period at Mar. 31, 2020	$ 2	$ (3,956)	296,726	(113,371)	179,401
Balance at end of period (in shares) at Mar. 31, 2020	23,015,781	(198,241)
Balance at beginning of period at Dec. 31, 2019	$ 2	$ (3,865)	288,345	(98,934)	185,548
Balance at beginning of period (in shares) at Dec. 31, 2019	22,496,999	(175,689)
Increase (Decrease) in Stockholders' Equity
Net loss					(28,747)
Balance at end of period at Jun. 30, 2020	$ 2	$ (3,956)	305,058	(127,681)	173,423
Balance at end of period (in shares) at Jun. 30, 2020	23,159,311	(204,048)
Balance at beginning of period at Mar. 31, 2020	$ 2	$ (3,956)	296,726	(113,371)	179,401
Balance at beginning of period (in shares) at Mar. 31, 2020	23,015,781	(198,241)
Increase (Decrease) in Stockholders' Equity
Issuance of restricted stock (in shares)	37,702
Forfeitures of restricted shares (in shares)		(5,807)
Exercise of stock options			1,159		1,159
Exercise of stock options (in shares)	105,828
Stock-based compensation expense			7,173		7,173
Net loss				(14,310)	(14,310)
Balance at end of period at Jun. 30, 2020	$ 2	$ (3,956)	$ 305,058	$ (127,681)	$ 173,423
Balance at end of period (in shares) at Jun. 30, 2020	23,159,311	(204,048)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (28,747)	$ (17,508)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	20,124	15,377
Amortization of deferred financing costs and debt discount	6,566	4,603
Deferred taxes	(3,875)	(6,633)
Stock-based compensation	14,310	13,758
Change in fair value of acquisition-related contingent consideration	600	3,006
Acquisition-related contingent consideration paid		(24,450)
Other noncash items		12
Changes in operating assets and liabilities, net of effect from acquisitions:
Accounts receivable, net	(7,773)	(2,383)
Inventories	(403)	(89)
Prepaid expenses and other current assets	3,815	(1,468)
Other assets	(4)	(140)
Accounts payable	(1,588)	(5,571)
Accrued expenses and other liabilities	(49)	5,661
Other long-term liabilities	412	(40)
Net cash provided by (used in) operating activities	3,388	(15,865)
Cash flows from investing activities:
Purchases of property and equipment	(1,447)	(3,508)
Software development costs	(8,898)	(6,618)
Proceeds from repayment of note receivable		1,000
Acquisitions of businesses, net of cash acquired		(158,762)
Net cash used in investing activities	(10,345)	(167,888)
Cash flows from financing activities:
Proceeds from exercise of stock options	2,312	1,536
Payments for debt financing costs		(9,477)
Repayments of line of credit		(45,000)
Payments of acquisition-related contingent consideration		(20,342)
Repayments of long-term debt and finance leases	(52)	(541)
Proceeds from issuance of convertible senior subordinated notes		325,000
Proceeds from sale of warrants		65,910
Purchase of convertible note hedges		(101,660)
Net cash provided by financing activities	2,260	215,426
Net (decrease) increase in cash and restricted cash	(4,697)	31,673
Cash and restricted cash, beginning of period	46,581	25,029
Cash and restricted cash, end of period	41,884	56,702
Supplemental disclosure of cash flow information:
Purchases of property and equipment and software development included in accounts payable and accrued expenses	239	291
Cash paid for interest	2,846	364
Cash paid for taxes	228	279
Interest costs capitalized to property and equipment and software development costs	$ 132	$ 148
Stock issued in connection with acquisitions		9,504

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Reconciliation of cash and restricted cash:
Cash	$ 38,752	$ 42,478	$ 52,137
Restricted cash	3,132	4,103	4,565
Total cash and restricted cash	$ 41,884	$ 46,581	$ 56,702	$ 25,029

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2020
Nature of Business
Nature of Business	1. Nature of Business ​ Tabula Rasa HealthCare, Inc. (the “Company”) focuses on optimizing drug regimens to reduce medication-related risk, specifically targeting adverse drug events, a large and growing medication therapy problem with an estimated cost of more than $528 billion annually in the United States (“U.S.”) and resulting in more than 275,000 deaths per year in the U.S. in 2018. The Company delivers a range of technology-enabled solutions, software, and services including what the Company believes to be the largest clinical tele-pharmacy network in the country, powered by the Company’s proprietary medication science technology, the Medication Risk Mitigation (“MRM”) Matrix, that are targeted at value-based payment models and support both state and federal regulations. The Company serves a number of different organizations within the healthcare industry, including more than 350 health plans, over 15,000 pharmacies and over 100 at-risk provider groups. ​

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	2. Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements ​ Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company's interim consolidated financial position for the periods indicated. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K filed on March 2, 2020 (“2019 Form 10-K”). ​ Effective January 1, 2020, in order to facilitate the administration, management, and development of the Company’s business and minimize the burden on the Company’s tax and regulatory reporting obligations, the Company implemented a reorganization pursuant to which all of the Company’s domestic subsidiaries, other than CK Solutions, LLC, merged with and into the Company’s wholly-owned subsidiary CareKinesis, Inc., which had previously changed its legal name on December 20, 2019 to TRHC OpCo, Inc. In the second quarter of 2020, TRHC OpCo, Inc. further changed its name to Tabula Rasa HealthCare Group, Inc. (“TRHC Group”). Following such reorganization, the Company’s only directly owned subsidiary is TRHC Group, which is the parent of CK Solutions, LLC and of three DoseMe foreign subsidiaries. ​ In conjunction with the Company’s reorganization, the Company now operates its business through two segments, CareVention HealthCare and MedWise HealthCare, effective January 1, 2020. Prior comparative periods have been revised to conform with the current period segment presentation. See Note 16 for a discussion of the Company’s reportable segments. ​ Risks Related to the COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency caused by a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this Quarterly Report on Form 10-Q. As such, it is uncertain as to the full magnitude of the impact that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and the ramification on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects that the COVID-19 outbreak may have on the Company’s results of operations, financial condition, or liquidity for 2020. However, the Company is dependent on its workforce to sell and deliver its products and services. Developments such as social distancing and shelter-in-place directives could impact the Company’s ability to deploy its workforce effectively. These same developments may affect the operations of the Company’s suppliers and customers, as their own workforces and operations are disrupted by efforts to curtail the spread of this virus. ​ As a result of the ongoing COVID-19 pandemic, the Company has experienced challenges with revenue growth. The pandemic has delayed the closing of contracts across both the Company’s CareVention HealthCare and MedWise HealthCare segments and, in some cases, shifted project timelines to 2021, resulting in fewer new business wins during the second quarter of 2020. Overall census growth for Programs of All-Inclusive Care for the Elderly (“PACE”) has remained below historical levels, which has affected the Company’s CareVention HealthCare segment growth. The Company’s MedWise HealthCare segment has also experienced delays in the timing of implementation and closing of new business. In addition, all major pharmacy tradeshows for the third quarter of 2020 have been cancelled, negatively impacting a key selling season for the Company’s PrescribeWellness business. However, the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which it relies . ​ Summary of Significant Accounting Policies ​ There have been no changes to the Company's significant accounting policies described in the 2019 Form 10-K that have had a material impact on the consolidated financial statements and related notes. ​ Recent Accounting Pronouncements ​ In June 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments ​ In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ​ In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement ​ In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ​ In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ). ​

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue
Revenue	3. Revenue ​ The Company generates revenue from its CareVention HealthCare and MedWise HealthCare segments. See Note 16 for additional discussion of the Company’s reportable segments. ​ Client contracts generally have a term of one 0 ​ CareVention HealthCare ​ PACE Product Revenue ​ The Company provides medication fulfillment pharmacy services to PACE, and while the majority of medications are routinely filled in order to treat chronic conditions, the mix and quantity of medications can vary. Revenue from medication fulfillment services is generally billed monthly and recognized when medications are delivered and control has passed to the client. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts. The Company does not experience a significant level of returns or reshipments. ​ PACE Solutions ​ The Company provides medication safety services and health plan management services to PACE organizations. These services include risk adjustment services, third party administration services, and electronic health records software. Revenue related to these services primarily consists of a fixed monthly fee assessed based on number of members served (“per member per month”) and subscription fees, which are recognized when the Company satisfies its performance obligation to stand ready to provide PACE services, which occurs when the Company’s clients have access to the PACE services. The Company generally bills for PACE services on a monthly basis. ​ MedWise HealthCare ​ Product Revenue ​ The Company provides COVID-19 test kits to pharmacies and other clients. Revenue from the sale of these products is generally billed monthly and is recognized as the Company satisfies its performance obligations to deliver the test kits and provide the test results to the pharmacies. The Company does not experience a significant level of returns or reshipments. ​ Medication Safety Services ​ The Company provides medication safety services, which include identification of high-risk individuals, medication regimen reviews including patient and prescriber counseling, and targeted interventions to increase adherence and close gaps in care. Revenue related to these services primarily consists of per member per month fees and fees for each medication review and assessment completed. Revenue is recognized when the Company satisfies its performance obligation to stand ready to provide medication safety services, which occurs when the Company’s clients have access to the medication safety service, and when medication reviews and assessments are completed. The Company generally bills for the medication safety services on a monthly basis. ​ Software Subscription and Services ​ ​ Disaggregation of Revenue ​ In the following table, revenue is disaggregated by reportable segment. Substantially all of the Company’s revenue is recognized in the U.S. and substantially all of the Company’s assets are located in the U.S. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ ​ 2020 ​ ​ 2019 ​ ​ 2020 ​ ​ 2019 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 38,930 ​ $ 33,372 ​ $ 76,017 ​ $ 64,354 PACE solutions ​ ​ 11,522 ​ ​ 11,437 ​ ​ 23,093 ​ ​ 22,611 ​ ​ $ 50,452 ​ $ 44,809 ​ $ 99,110 ​ $ 86,965 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 443 ​ $ — ​ $ 443 ​ $ — Medication safety services ​ ​ 15,707 ​ ​ 22,498 ​ $ 30,027 ​ ​ 37,849 Software subscription and services ​ ​ 10,232 ​ ​ 8,948 ​ ​ 20,081 ​ ​ 12,400 ​ ​ $ 26,382 ​ $ 31,446 ​ $ 50,551 ​ $ 50,249 Total revenue ​ $ 76,834 ​ $ 76,255 ​ $ 149,661 ​ $ 137,214 ​ Contract Balances ​ Assets and liabilities related to the Company’s contracts are reported on a contract-by-contract basis at the end of each reporting period. Contract balances consist of contract assets and contract liabilities. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. Contract assets are classified as current or non-current based on the timing of the Company’s rights to the unconditional payments. Contract assets are generally classified as current and recorded within other current assets on the Company’s consolidated balance sheets. ​ Contract liabilities include advance customer payments and billings in excess of revenue recognized. The Company generally classifies contract liabilities in accrued expenses and other current liabilities and in other long-term liabilities on the Company’s consolidated balance sheets. The Company anticipates that it will satisfy most of its performance obligations associated with its contract liabilities within a year. ​ The following table provides information about the Company’s contract assets and contract liabilities from contracts with clients as of June 30, 2020 and December 31, 2019. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2020 2019 Contract assets ​ $ 3,595 ​ $ 6,165 Contract liabilities ​ ​ 6,719 ​ ​ 4,930 ​ Significant changes in the contract assets and the contract liabilities balances during the six months ended June 30, 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2020 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 6,165 Decreases due to cash received ​ ​ (4,147) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 394 Increases, net of reclassifications to receivables ​ ​ 1,183 Contract assets, end of period ​ $ 3,595 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 4,930 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (3,614) Increases due to cash received, excluding amounts recognized as revenue during the period ​ ​ 5,403 Contract liabilities, end of period ​ $ 6,719 ​ During the six months ended June 30, 2019, the Company recognized $1,408 of revenue that was included in the December 31, 2018 contract liability balance of $1,733.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2020
Net (Loss) Income per Share
Net (Loss) Income per Share	4. Net Loss per Share ​ Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period plus the impact of dilutive securities using the treasury stock method, to the extent that they are not anti-dilutive. ​ The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ 2020 ​ 2019 ​ 2020 ​ 2019 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (14,310) ​ $ (6,529) ​ $ (28,747) ​ $ (17,508) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 21,556,646 ​ ​ 20,482,032 ​ ​ 21,465,772 ​ ​ 20,433,564 Net loss per share, basic and diluted ​ $ (0.66) ​ $ (0.32) ​ $ (1.34) ​ $ (0.86) ​ The following potential common shares, presented based on amounts outstanding for the three and six months ended June 30, 2020 and 2019, were excluded from the calculation of diluted net loss per share for three and six months ended June 30, 2020 and 2019 because including them would have had an anti-dilutive effect. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2020 2019 Stock options to purchase common stock ​ 2,498,663 ​ 2,948,279 Unvested restricted stock ​ 1,322,064 ​ 1,445,817 Common stock warrants ​ 4,646,393 ​ 4,646,393 Contingently issuable shares ​ 58,409 ​ 5,000 ​ ​ 8,525,529 ​ 9,045,489 ​ ​ ​ Shares associated with the conversion of the convertible senior subordinated notes have been excluded from the table above.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2020
Acquisitions
Acquisitions	5. Acquisitions ​ PrescribeWellness ​ On March 5, 2019, the Company entered into, and consummated the transactions contemplated by, a Merger Agreement (the “Merger Agreement”) with Prescribe Wellness, LLC, a Nevada limited liability company (“PrescribeWellness”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial Holder Representative. PrescribeWellness was a standalone entity and was a leading cloud-based patient engagement solutions company that facilitated collaboration for more than 12,000 pharmacies with patients, payers, providers, and pharmaceutical companies. The Company paid $150,000 in cash consideration upon closing, subject to certain customary adjustments as set forth in the Merger Agreement. The acquisition was considered an asset acquisition for tax purposes and accordingly, the goodwill and amortization of intangible assets resulting from the acquisition is deductible for tax purposes. See Note 5 set forth in the Company’s audited financial statements included as part of the 2019 Form 10-K for additional information on the PrescribeWellness acquisition. ​ Revenue from PrescribeWellness is primarily comprised of subscription fees for its cloud-based patient engagement solutions. Revenue for these services, and the related costs, is recognized each month as performance obligations are satisfied and costs are incurred, and is included in service revenue and cost of revenue – service cost, respectively, in the Company’s consolidated statements of operations. For the three and six months ended June 30, 2019, service revenue of $7,919 and $10,110, respectively, from PrescribeWellness was included in the Company’s consolidated statements of operations. Service revenue was recorded net of a reduction of $544 and $747 for the three and six months ended June 30, 2019, respectively, due to the purchase accounting effects of recording deferred revenue at fair value. Net loss of $2,925 and $3,796, which included amortization of $3,277 and $4,151 associated with acquired intangible assets, from PrescribeWellness, was included in the Company’s consolidated statements of operations for the three and six months ended June 30, 2019, respectively. ​ DoseMe ​ On January 2, 2019, the Company completed the acquisition of all of the outstanding share capital and options to purchase the share capital of DoseMe Holdings Pty Ltd, a proprietary company limited by shares organized under the Laws of Australia (“DoseMe”). DoseMe is the developer of DoseMeRx, an advanced precision dosing tool that helps physicians and pharmacists accurately dose patients’ high-risk parenteral (intravenous) medications based on individual needs. The acquisition was made pursuant to a Share Purchase Deed, made and entered into as of November 30, 2018. The consideration for the acquisition was comprised of (i) cash consideration of $10,000 paid at closing, subject to certain customary post-closing adjustments as set forth in the Share Purchase Deed, (ii) the issuance of 149,053 shares of the Company’s common stock, and (iii) the potential for a contingent earn-out payment, based on the financial performance of DoseMe. During the third quarter of 2019, the Company paid $8,750 in cash in full satisfaction of the contingent purchase price consideration. The acquisition was considered an asset acquisition for tax purposes and accordingly, the goodwill and amortization of intangible assets resulting from the acquisition is deductible for U.S. tax purposes. See Note 5 set forth in the Company’s audited financial statements included as part of the 2019 Form 10-K for additional information on the DoseMe acquisition. ​ Revenue from DoseMe is primarily comprised of subscription and license fees for use of DoseMe’s advanced precision dosing software tool. Revenue for these services, and the related costs, is recognized each month as performance obligations are satisfied and costs are incurred, and is included in service revenue and cost of revenue – service cost, respectively, in the Company’s consolidated statements of operations. Service revenue of $72 and $138 and net loss of $769 and $1,995, which included amortization of $579 and $1,141 associated with acquired intangible assets, from DoseMe were included in the Company’s consolidated statements of operations for the three and six months ended June 30, 2019, respectively. ​ Pro forma ​ The unaudited pro forma results presented below include the results of the aforementioned acquisitions as if they had been consummated as of January 1, 2018. The unaudited pro forma results include the amortization associated with acquired intangible assets, interest expense on the debt incurred to fund these acquisitions, insurance expense for additional required business insurance coverage, stock-based compensation expense related to equity awards granted to employees of the acquired companies, adjustments to revenue for the purchase accounting effects of recording deferred revenue at fair value, and the estimated tax effect of adjustments to income (loss) before income taxes. Material nonrecurring charges, including direct acquisition costs, directly attributable to the transactions are excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2018. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2019 ​ 2019 Revenue ​ $ 76,255 ​ $ 142,961 Net loss ​ ​ (6,395) ​ ​ (18,104) ​ ​ ​ ​

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2020
Property and Equipment.
Property and Equipment	6. Property and Equipment ​ Accumulated depreciation was $15,701 and $13,728 as of June 30, 2020 and December 31, 2019, respectively. Depreciation expense on property and equipment for the three months ended June 30, 2020 and 2019 was $1,234 and $1,089, respectively. Depreciation expense on property and equipment for the six months ended June 30, 2020 and 2019 was $2,502 and $2,097 , respectively. ​

Software Development Costs

Software Development Costs	6 Months Ended
	Jun. 30, 2020
Software Development Costs
Software Development Costs	7. Software Development Costs ​ The Company capitalizes certain costs incurred in connection with obtaining or developing its proprietary software platforms, which are used to support its service contracts, including external direct costs of material and services, payroll costs for employees directly involved with the software development, and interest expense related to the borrowings attributable to software development. As of June 30, 2020 31, ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Software development costs $ 38,607 ​ $ 29,714 Less: accumulated amortization ​ (15,185) ​ ​ (11,213) Software development costs, net $ 23,422 ​ $ 18,501 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 2,148 ​ $ 3,294 ​ Amortization expense for the three months ended June 30, 2020 and 2019 was $2,154 and $905, respectively. Amortization expense for the six months ended June 30, 2020 and 2019 was $3,977 and $1,529, respectively. ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets ​ Intangible assets consisted of the following as of June 30, 2020 and December 31, 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 3.5 ​ $ 11,255 ​ $ (4,577) ​ $ 6,678 Client relationships ​ 12.2 ​ ​ 128,169 ​ ​ (26,528) ​ ​ 101,641 Non-competition agreements ​ 5.0 ​ ​ 6,602 ​ ​ (3,302) ​ ​ 3,300 Developed technology ​ 8.0 ​ ​ 68,593 ​ ​ (20,398) ​ ​ 48,195 Patient database ​ 5.0 ​ ​ 21,700 ​ ​ (5,787) ​ ​ 15,913 Domain name ​ 10.0 ​ ​ 59 ​ ​ (18) ​ ​ 41 Total intangible assets ​ ​ ​ $ 236,378 ​ $ (60,610) ​ $ 175,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 7.1 ​ $ 11,255 ​ $ (3,845) ​ $ 7,410 Client relationships ​ 12.2 ​ ​ 128,169 ​ ​ (20,977) ​ ​ 107,192 Non-competition agreements ​ 5.0 ​ ​ 6,602 ​ ​ (2,641) ​ ​ 3,961 Developed technology ​ 8.0 ​ ​ 68,593 ​ ​ (15,870) ​ ​ 52,723 Patient database ​ 5.0 ​ ​ 21,700 ​ ​ (3,617) ​ ​ 18,083 Domain name ​ 10.0 ​ ​ 59 ​ ​ (15) ​ ​ 44 Total intangible assets ​ ​ ​ $ 236,378 ​ $ (46,965) ​ $ 189,413 ​ Amortization expense for intangible assets for the three months ended June 30, 2020 and 2019 was $6,823 and $7,084, respectively. Amortization expense for intangible assets for the six months ended June 30, 2020 and 2019 was $13,645 and $11,751, respectively. ​ The estimated amortization expense for the remainder of 2020 and each of the next five years and thereafter is as follows: ​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2020 (July 1 - December 31) $ 16,584 2021 ​ ​ 26,972 2022 ​ ​ 25,646 2023 ​ ​ 24,436 2024 ​ ​ 17,433 2025 ​ ​ 11,565 Thereafter ​ ​ 53,132 Total estimated amortization expense ​ $ 175,768 ​

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2020
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	9. Accrued Expenses and Other Liabilities ​ As of June 30, 2020 and December 31, 2019, accrued expenses and other liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Employee related expenses ​ $ 9,122 ​ $ 12,582 Contract liability ​ ​ 6,234 ​ ​ 4,857 Client funds obligations* ​ ​ 3,132 ​ ​ 4,106 Contract labor ​ ​ 2,143 ​ ​ 329 Interest ​ ​ 2,133 ​ ​ 2,133 Professional fees ​ ​ 247 ​ ​ 337 Royalties expense ​ ​ 180 ​ ​ 17 Non-income taxes payable ​ ​ 1,043 ​ ​ 898 Other expenses ​ ​ 2,710 ​ ​ 1,647 Total accrued expenses and other liabilities ​ $ 26,944 ​ $ 26,906 ​ *This amount represents clients’ funds held by the Company, with an offsetting amount included in restricted cash.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	6 Months Ended
	Jun. 30, 2020
Lines of Credit and Long-Term Debt
Lines of Credit and Long-Term Debt	10. Lines of Credit and Long-Term Debt ​ (a) Lines of Credit ​ On September 6, 2017, the Company entered into an Amended and Restated Loan and Security Agreement (as subsequently amended, the “Amended and Restated 2015 Line of Credit”), whereby the Company amended and restated its revolving line of credit, originally entered into with Bridge Bank (now Western Alliance Bank) in 2015. The Amended and Restated 2015 Line of Credit provides for borrowing availability in an aggregate amount up to $60,000 to be used for general corporate purposes, with a $1,000 sublimit for cash management services, letters of credit and foreign exchange transactions. The Amended and Restated 2015 Line of Credit matures on September 6, 2020. ​ Interest on the Amended and Restated 2015 Line of Credit is calculated at a variable rate based upon Western Alliance Bank's prime rate plus an applicable margin which will range from (0.25%) to 0.25% depending on the Company’s leverage ratio, with Western Alliance Bank's prime rate having a floor of 3.5%. ​ As of June 30, 2020, the Company was in compliance with all covenants related to the Amended and Restated 2015 Line of Credit. ​ As of June 30, 2020, the Company has an outstanding letter of credit of $200 issued pursuant to the Amended and Restated 2015 Line of Credit in connection with the Company’s lease agreement for the office space in Moorestown, NJ. The letter of credit renews annually and expires in September 2027 and reduces amounts available under the Amended and Restated 2015 Line of Credit. ​ As of June 30, 2020 and December 31, 2019, there were no amounts outstanding under the Amended and Restated 2015 Line of Credit. Amounts available for borrowings under the Amended and Restated 2015 Line of Credit were $59,800 as of June 30, 2020. ​ As of June 30, 2020, the interest rate on the Amended and Restated 2015 Line of Credit was 5.58%. No interest expense was incurred for the three and six months ended June 30, 2020 as there were no aggregate borrowings outstanding during the three and six months ended June 30, 2020. As of June 30, 2019, the interest rate on the Amended and Restated 2015 Line of Credit was 5.58% and interest expense was $351 for the six months ended June 30, 2019. No interest expense was incurred for the three months ended June 30, 2019 as there were no aggregate borrowings outstanding related to the Amended and Restated 2015 Line of Credit for the three months ended June 30, 2019. ​ In connection with the Amended and Restated 2015 Line of Credit (and all predecessor agreements prior to the amendment or the amendment and restatement thereof), the Company recorded deferred financing costs of $793. The Company is amortizing the deferred financing costs to interest expense using the effective-interest method over the term of the Amended and Restated 2015 Line of Credit and amortized $99 and $61 to interest expense for the three months ended June 30, 2020 and 2019, respectively, and $199 and $109 for the six months ended June 30, 2020 and 2019, respectively. Deferred financing costs of $67 and $266, net of accumulated amortization, are included in other assets on the accompanying consolidated balance sheets as of June 30, 2020 and December 31, 2019, respectively. ​ (b) Convertible Senior Subordinated Notes ​ On February 12, 2019, the Company issued and sold an aggregate principal amount of $325,000 of 1.75% convertible senior subordinated notes (the “2026 Notes”) in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended. The 2026 Notes bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2019. The notes will mature on February 15, 2026, unless earlier converted or repurchased. The initial conversion rate for the notes is 14.2966 shares of the Company’s common stock per $1 principal amount of notes. This conversion rate is equal to an initial conversion price of approximately $69.95 per share of the Company’s common stock. ​ Holders may convert all or any portion of their at any time prior to the close of business on the business day immediately preceding August 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the measurement period) in which the trading price (as defined in the indenture governing the 2026 Notes) per $1 principal amount of 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change or make-whole fundamental change (as defined in the indenture governing the 2026 Notes) or a transaction resulting in the Company’s common stock converting into other securities or property or assets. On or after August 15, 2025 until the close of business on the first scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2026 Notes regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver shares of our common stock, cash or a combination thereof at the Company’s option. As of June 30, 2020, none of the conditions allowing holders of the 2026 Notes to convert had been met. ​ In accounting for the issuance of the 2026 Notes, the Company separated the 2026 Notes into liability and equity components. The carrying amount of the equity component representing the conversion option was $102,900 and was determined by deducting the fair value of the liability component from the par value of the 2026 Notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. The initial associated deferred tax effect of $25,884 was recorded as a reduction of additional paid-in capital because the equity component is not currently expected to be deductible for income tax purposes. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense over the term of the 2026 Notes at an effective interest rate of 8.05% over the contractual term. ​ Debt issuance costs related to the 2026 Notes of $9,372 were allocated to the liability and equity components of the 2026 Notes based on their relative values. Issuance costs attributable to the liability component were $6,405 and will be amortized to interest expense using the effective interest method over the contractual term. Issuance costs attributable to the equity component were netted with the equity component in stockholders’ equity. ​ During the three months ended June 30, 2020, the Company recognized $4,638 of interest expense related to the 2026 Notes, of which $1,423 was accrued and $3,215 was non-cash accretion of the debt discounts recorded. During the six months ended June 30, 2020, the Company recognized $9,211 of interest expense related to the 2026 Notes, of which $2,844 was accrued and $6,367 was non-cash accretion of the debt discounts recorded. ​ During the three months ended June 30, 2019, the Company recognized $4,389 of interest expense related to the 2026 Notes, of which $1,422 was accrued and $2,967 was non-cash accretion of the debt discounts recorded. During the six months ended June 30, 2019, the Company recognized $6,659 of interest expense related to the 2026 Notes, of which $2,164 was accrued and $4,494 was non-cash accretion of the debt discounts recorded. ​ The 2026 Notes have been, and will be, classified as long-term debt on the Company’s consolidated balance sheets until such 2026 Notes are within one year of maturity. The 2026 Notes have a carrying value of $232,658 as of June 30, 2020. Accrued interest payable on the 2026 Notes of $2,133 as of June 30, 2020 is included in accrued expenses and other liabilities on the consolidated balance sheet. ​ (c) Convertible Note Hedge and Warrant Transactions ​ In connection with the offering of the 2026 Notes, the Company entered into convertible note hedge transactions with affiliates of certain of the initial purchasers (the “option counterparties”) of the 2026 Notes pursuant to the terms of call option confirmations. The Company has the option to purchase a total of 4,646,393 shares of its common stock at a price of approximately As these instruments are considered indexed to the Company's own stock and are considered equity classified, the convertible note hedges and warrants are recorded in stockholders’ equity, are not accounted for as derivatives and are not remeasured each reporting period. The net costs incurred in connection with the convertible note hedge and warrant transactions were recorded as a reduction to additional paid-in capital on the Company’s consolidated balance sheets. ​ The convertible note hedge transactions are expected generally to reduce the potential dilution to the Company’s common stock upon conversion of the 2026 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2026 Notes, as the case may be. The warrant transactions could separately have a dilutive effect on the Company’s common stock to the extent that the market price per share of the Company’s common stock exceeds the strike price of the warrants. ​ (d) Long-Term Debt ​ The following table represents the total long-term debt obligations of the Company at June 30, 2020 and December 31, 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Convertible senior subordinated notes ​ $ 325,000 ​ $ 325,000 Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (92,342) ​ ​ (98,709) Convertible senior subordinated notes, net ​ ​ 232,658 ​ ​ 226,291 Finance leases ​ ​ 8 ​ ​ 128 Total long-term debt and finance leases, net ​ ​ 232,666 ​ ​ 226,419 Less current portion, net ​ ​ (8) ​ ​ (125) Total long-term debt and finance leases, less current portion, net ​ $ 232,658 ​ $ 226,294 ​ ​ ​ ​ ​ ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Taxes
Income Taxes	11. Income Taxes ​ For the six months ended June 30, 2020, the Company recorded an income tax benefit of $3,875, which resulted in an effective tax rate of 11.9%. The effective tax rate differs from the U.S. statutory tax rate primarily due to an increase in the valuation allowance that is currently limiting the realizability of the Company’s net deferred tax assets as of June 30, 2020. Accordingly, the year to date tax benefit was limited due to unbenefited losses in the six months ended June 30, 2020. The Company calculates its provision for income taxes during its interim periods by applying the estimated annual effective tax rate for the full year ordinary income or loss to the respective reporting period’s year to date income or loss, while also adding any income tax expense or benefit related to discrete items occurring within that interim period. ​ For the six months ended June 30, 2019, the Company recorded an income tax benefit of $6,580, which resulted in an effective tax rate of 27.3%. The tax benefit primarily consists of $3,884 based on the estimated effective tax rate for the full year and $2,186 of windfall tax benefits generated from the vesting of restricted stock, disqualifying dispositions and exercising of nonqualified stock options during the period. ​

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Stockholders' Equity
Stockholders' Equity	12. Stockholders' Equity ​ In connection with the offering of the 2026 Notes, the Company issued warrants ​

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Stock-Based Compensation
Stock-Based Compensation	13. Stock-Based Compensation ​ In September 2016, the Company adopted the 2016 Equity Compensation Plan (“2016 Plan”). During the term of the 2016 Plan, the share reserve will automatically increase on the first trading day in January of each calendar year by an amount equal to the lesser of 5% of the total number of outstanding shares of common stock on the last trading day in December of the prior calendar year or such other number set by the Company’s Board of Directors (the “Board”). In accordance with the terms of the 2016 Plan, the share reserve increased by 1,116,065 shares on January 2, 2020. As of June 30, 2020, 1,128,118 shares were available for future grants under the 2016 Plan. ​ Restricted Common Stock ​ The following table summarizes the restricted stock award activity under the 2016 Plan for the six months ended June 30, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2019 ​ 1,213,581 ​ $ 37.69 Granted ​ 428,656 ​ ​ 66.65 Vested ​ (280,995) ​ ​ 45.39 Forfeited ​ (39,178) ​ ​ 55.72 Outstanding at June 30, 2020 ​ 1,322,064 ​ $ 44.91 ​ For the three months ended June 30, 2020 and 2019, $4,809 and $3,361 of expense was recognized related to restricted stock awards, respectively. For the six months ended June 30, 2020 and 2019, $8,948 and $6,086 of expense was recognized related to restricted stock awards, respectively. As of June 30, 2020, there was unrecognized compensation expense of $47,428 related to non-vested restricted stock awards under the 2016 Plan, which is expected to be recognized over a weighted average period of 2.9 years. ​ Performance-Based Equity Awards ​ On August 6, 2018, the Board approved the grant of a performance-based stock award to a consultant pursuant to the 2016 Plan. The award provided that 50,000 shares of common stock would be issued based on the achievement of certain milestones. The award had a grant-date fair value of $61.85 per share based on the Company’s closing stock price on the grant date. Compensation cost was recognized over the service period based on management’s determination that it was probable that the milestones would be achieved. As of December 31, 2019, all milestones were achieved and there was no unrecognized compensation expense related to the performance-based stock award. During the first quarter of 2020, the Company issued 5,000 shares of common stock related to this award for the achievement of the final milestone. For the three and six months ended June 30, 2019, the Company recorded $399 and $1,314 of expense related to the performance-based stock award. ​ On May 4, 2020, pursuant to the 2016 Plan, the Board approved grants totaling 10,686 shares of restricted stock to an employee. The grants vest subject to certain performance conditions being achieved during the two-year period ending March 2, 2022. The awards have a grant-date fair value of $56.14 per share based on the Company’s closing stock price on the grant date. Stock compensation costs associated with these grants are recognized over the service period based upon the Company’s assessment of the probability that the performance conditions will be achieved. The Company recognized no stock compensation expense related to these grants for the three and six months ended June 30, 2020 as the achievement of the underlying performance conditions was considered unlikely. As of June 30, 2020, there was $600 of cumulative unrecognized compensation expense related to these performance-based restricted stock awards. ​ Other Stock Awards ​ During the first quarter of 2020, the Board approved the grant of stock awards to select employees pursuant to the 2016 Plan. The awards provided for the issuance of 9,386 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $52.29 per share. For the six months ended June 30, 2020, the Company recorded $491 of expense related to these stock awards. ​ During the six months ended June 30, 2019, the Board approved the grant of stock awards to select employees and a non-employee director pursuant to the 2016 Plan. The awards provide for the issuance of 19,648 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $53.03 per share. For the three and six months ended June 30, 2019, the Company recorded $504 and $1,042 of expense related to these stock awards. ​ Stock Options ​ The Company recorded $2,364 and $2,642 of stock-based compensation expense related to employee and non-employee stock options for the three months ended June 30, 2020 and 2019, respectively. The Company recorded $4,871 and $5,316 of stock-based compensation expense related to employee and non-employee stock options for the six months ended June 30, 2020 and 2019, respectively. The Company records forfeitures as they occur. ​ The estimated fair value of options granted was calculated using a Black-Scholes option-pricing model. The computation of expected life for employees was determined based on the simplified method. The risk-free rate is based on the U.S. Treasury security with terms equal to the expected time of exercise as of the grant date. The Company's common stock had not been publicly traded until its IPO commenced on September 29, 2016; therefore, expected volatility is based on a combination of the historical volatilities of the Company’s common stock and the historical volatilities of selected public companies whose services are comparable to that of the Company. The table below sets forth the weighted average assumptions for employee grants during the six months ended June 30, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, Valuation assumptions: 2020 2019 Expected volatility ​ 56.10 % ​ 69.60 % Expected term (years) ​ 5.25 ​ ​ 6.02 ​ Risk-free interest rate ​ 1.22 % ​ 2.50 % Dividend yield ​ — ​ ​ — ​ ​ The weighted average grant date fair value of employee options granted during the six months ended June 30, 2020 and 2019 was $33.78 and $34.94 per share, respectively. ​ The following table summarizes stock option activity under the 2016 Plan for the six months ended June 30, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2019 ​ 2,755,343 ​ $ 25.10 ​ ​ ​ ​ Granted ​ 5,000 ​ ​ 68.10 ​ ​ ​ ​ ​ Exercised ​ (223,980) ​ ​ 11.11 ​ ​ ​ ​ ​ Forfeited ​ (37,700) ​ ​ 48.73 ​ ​ ​ ​ ​ Outstanding at June 30, 2020 ​ 2,498,663 ​ $ 26.08 ​ 6.6 ​ $ 73,296 Options vested and expected to vest at June 30, 2020 ​ 2,498,663 ​ $ 26.08 ​ 6.6 ​ $ 73,296 Exercisable at June 30, 2020 ​ 1,715,578 ​ $ 18.48 ​ 5.9 ​ $ 62,853 ​ The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the Company’s closing stock price or estimated fair value on the last trading day of the fiscal quarter for those stock options that had exercise prices lower than the fair value of the Company's common stock. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised during the six months ended June 30, 2020 and 2019 was $9,656 and $5,959, respectively. ​ As of June 30, 2020, there was $19,044 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 2.3 years. ​ Cash received from option exercises for the six months ended June 30, 2020 and 2019 was $2,312 and $1,536, respectively. ​ The Company recorded total stock-based compensation expense for the three and six months ended June 30, 2020 and 2019 in the following expense categories of its consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2020 2019 2020 2019 Cost of revenue - product ​ $ 193 ​ $ 313 ​ $ 375 ​ $ 622 Cost of revenue - service ​ ​ 839 ​ ​ 994 ​ ​ 1,602 ​ ​ 1,978 Research and development ​ ​ 1,071 ​ ​ 1,806 ​ ​ 2,480 ​ ​ 4,088 Sales and marketing ​ ​ 523 ​ ​ 1,105 ​ ​ 1,051 ​ ​ 2,092 General and administrative ​ ​ 4,547 ​ ​ 2,688 ​ ​ 8,802 ​ ​ 4,978 Total stock-based compensation expense ​ $ 7,173 ​ $ 6,906 ​ $ 14,310 ​ $ 13,758 ​ ​ ​ ​

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Measurements
Fair Value Measurements	14. Fair Value Measurements ​ The Company’s financial instruments consist of accounts receivable, contract assets, accounts payable, contract liabilities, accrued expenses, acquisition-related contingent consideration, and long-term debt, which includes the Company’s convertible senior subordinated notes and finance leases. The carrying values of accounts receivable, contract assets, accounts payable, contract liabilities, and accrued expenses are representative of their fair value due to the relatively short-term nature of those instruments. See below for additional information on the Company’s convertible senior subordinated notes. ​ The Company has classified liabilities measured at fair value on a recurring basis at June 30, 2020 and December 31, 2019 as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 June 30, 2020 Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related contingent consideration - long-term ​ $ — ​ $ — ​ $ 11,400 ​ $ 11,400 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 December 31, 2019 Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related contingent consideration - long-term ​ $ — ​ $ — ​ $ 10,800 ​ $ 10,800 ​ Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. The acquisition-related contingent consideration liability represents the estimated fair value of the additional cash and equity consideration payable that is contingent upon the achievement of certain financial and performance milestones. In accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations, ​ In connection with the acquisition of the Cognify business, additional consideration may be payable by the Company based on a multiple of the excess of certain PACE solutions’ 2021 revenues and Adjusted EBITDA over their 2018 revenues and Adjusted EBITDA, as defined in the stock purchase agreement. The Cognify acquisition-related contingent consideration, which is liability-classified, was recorded at the estimated fair value at the acquisition date of October 19, 2018. The Company, with the assistance of a third-party appraiser, utilized a Monte Carlo simulation to derive estimates of the contingent consideration payments as of the acquisition date and at each subsequent period. During the three months ended June 30, 2020, the Company recorded a $100 remeasurement gain for the change in the fair value of the Cognify acquisition-related contingent consideration liability primarily due to a decrease in the forecasted Adjusted EBITDA used in the contingent consideration payment calculation, which was offset by the impact of a decreased discount period to the final measurement date. During the six months ended June 30, 2020, the Company recorded a $600 charge for the change in the fair value of Cognify acquisition-related contingent consideration primarily due to a decreased discount period to the final measurement date. During the three and six months ended June 30, 2019, the Company recorded a $1,500 and $2,400 charge, respectively, for the change in the fair value of Cognify acquisition-related contingent consideration primarily due to a decreased discount period to the final measurement date. ​ The fair value of the Cognify acquisition-related contingent consideration was calculated to be $11,400 and $10,800 as of June 30, 2020 and December 31, 2019, respectively. The final amount of the contingent consideration liability will be fixed as of December 31, 2021. The maximum contingent consideration amount that could be earned under the stock purchase agreement is $14,000. ​ The changes in fair value of the Company’s acquisition-related contingent consideration for the six months ended June 30, 2020 were as follows: ​ ​ ​ ​ ​ Balance at December 31, 2019 $ 10,800 Adjustments to fair value measurement ​ ​ 600 Balance at June 30, 2020 ​ $ 11,400 ​ The following table presents the financial instruments that are not carried at fair value but require fair value disclosure as of June 30, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 232,658 ​ $ 332,111 ​ The fair value of the 2026 Notes at each balance sheet date is determined based on recent quoted market prices for these notes which is a Level 2 measurement. As discussed in Note 10, the 2026 Notes are carried at their aggregate face value of $325,000 , less any unaccreted debt discount and unamortized debt issuance costs. ​

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies
Commitments and Contingencies	15. Commitments and Contingencies ​ (a) Legal Proceedings ​ The Company is not currently involved in any significant claims or legal actions that, in the opinion of management, are expected to have a material adverse impact on the Company. ​ (b) Vendor Purchase Agreements ​ In May 2016, the Company signed a prime vendor agreement with AmerisourceBergen Drug Corporation (“AmerisourceBergen”). The agreement was not renewed upon expiration in April 2019, but the Company continues to purchase from AmerisourceBergen from time to time on a purchase order basis. Pursuant to the terms of a security agreement entered into in connection with the prime vendor agreement, which still remains in place, AmerisourceBergen also holds a subordinated security interest in all of the Company’s assets. ​ On March 29, 2019, the Company entered into an Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement (the “Prior Thrifty Drug Agreements”) with Thrifty Drug Stores, Inc. (“Thrifty Drug”) to replace the prime vendor agreement with AmerisourceBergen. On July 1, 2020, the Company entered into a new Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement with Thrifty Drug (the “Thrifty Drug Agreements”) to replace the Prior Thrifty Drug Agreements, which, among other things, extended the Company’s agreement with Thrifty Drug through September 30, 2023. Pursuant to the terms of the Thrifty Drug Agreements, the Company has agreed to purchase not less than 98% of the Company’s total prescription product requirements from Thrifty Drug. The Company commenced purchasing prescription products under the Prior Thrifty Drug Agreements in May 2019 and has continued to do so under the Thrifty Drug Agreements beginning in July 2020. Both the Prior Thrifty Drug Agreements and the Thrifty Drug Agreements authorize Thrifty Drug to hold a security interest in all of the products purchased by the Company under the respective agreements. ​ As of June 30, 2020, the Company had $2,399 due to AmerisourceBergen and Thrifty Drug as a result of prescription drug purchases. As of December 31, 2019, the Company had $2,465 due to AmerisourceBergen and Thrifty Drug as a result of prescription drug purchases. ​ In December 2019, the Company entered into an updated agreement with its data aggregation partner related to the Company’s pharmacy cost management services. The agreement is effective January 1, 2020 with a three-year term expiring December 31, 2022 and commits the Company to a monthly minimum purchase obligation of $30. ​ ​

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting
Segment Reporting	16. Segment Reporting ​ The Company operates its business through two segments. The Company's chief operating decision maker (“CODM”), the Chief Executive Officer, allocates resources and assesses performance based upon financial information at the reportable segment level. Substantially all revenues are generated and substantially all tangible assets are held in the U.S. The Company classifies its operations into two reportable segments as follows: ​ CareVention HealthCare primarily provides services to PACE organizations that include medication fulfillment pharmacy services and PACE solutions such as medication safety services and health plan management services. ​ MedWise HealthCare clients include health plans, pharmacies, and healthcare providers. Services provided to these clients include medication safety services and software subscription solutions, . ​ Shared services primarily consist of unallocated corporate sales and marketing expenses and general and administrative expenses associated with the management and administration of the Company’s business objectives. ​ The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. ​ Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of the Company’s businesses and may be different than similarly-titled segment performance financial measures used by other companies. ​ Adjusted EBITDA is defined as net income (loss) plus certain other expenses, which includes interest expense, provision (benefit) for income tax, depreciation and amortization, change in fair value of acquisition-related contingent consideration expense (income), acquisition-related expense and stock-based compensation expense. The Company ​ Management considers revenue and Adjusted EBITDA to be the appropriate metric to evaluate and compare the ongoing operating performance of the Company’s segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. ​ The following tables present the Company’s segment information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ MedWise HealthCare ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 38,930 ​ $ 443 ​ $ 39,373 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 11,522 ​ ​ — ​ ​ 11,522 Medication safety services ​ ​ — ​ ​ 15,707 ​ ​ 15,707 Software subscription and services ​ ​ — ​ ​ 10,232 ​ ​ 10,232 Total service revenue ​ ​ 11,522 ​ ​ 25,939 ​ ​ 37,461 Total revenue ​ $ 50,452 ​ $ 26,382 ​ $ 76,834 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 33,372 ​ $ — ​ $ 33,372 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 11,437 ​ ​ — ​ ​ 11,437 Medication safety services ​ ​ — ​ ​ 22,498 ​ ​ 22,498 Software subscription and services ​ ​ — ​ ​ 8,948 ​ ​ 8,948 Total service revenue ​ ​ 11,437 ​ ​ 31,446 ​ ​ 42,883 Total revenue ​ $ 44,809 ​ $ 31,446 ​ $ 76,255 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 76,017 ​ $ 443 ​ $ 76,460 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 23,093 ​ ​ — ​ ​ 23,093 Medication safety services ​ ​ — ​ ​ 30,027 ​ ​ 30,027 Software subscription and services ​ ​ — ​ ​ 20,081 ​ ​ 20,081 Total service revenue ​ ​ 23,093 ​ ​ 50,108 ​ ​ 73,201 Total revenue ​ $ 99,110 ​ $ 50,551 ​ $ 149,661 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 64,354 ​ $ — ​ $ 64,354 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 22,611 ​ ​ — ​ ​ 22,611 Medication safety services ​ ​ — ​ ​ 37,849 ​ ​ 37,849 Software subscription and services ​ ​ — ​ ​ 12,400 ​ ​ 12,400 Total service revenue ​ ​ 22,611 ​ ​ 50,249 ​ ​ 72,860 Total revenue ​ $ 86,965 ​ $ 50,249 ​ $ 137,214 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ MedWise HealthCare ​ Shared Services ​ Consolidated Adjusted EBITDA (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 12,077 ​ $ 4,697 ​ $ (9,640) ​ $ 7,134 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 11,466 ​ $ 9,059 ​ $ (6,873) ​ $ 13,652 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 23,825 ​ $ 7,528 ​ $ (19,412) ​ $ 11,941 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 22,086 ​ $ 10,707 ​ $ (13,450) ​ $ 19,343 ​ The following table presents the Company’s reconciliation of the segments’ total Adjusted EBITDA to net loss as presented in the consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2020 2019 2020 2019 Reconciliation of net loss to Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (14,310) ​ $ (6,529) ​ $ (28,747) ​ $ (17,508) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 4,668 ​ ​ 4,308 ​ ​ 9,278 ​ ​ 7,001 Income tax benefit ​ ​ (508) ​ ​ (2,539) ​ ​ (3,875) ​ ​ (6,580) Depreciation and amortization ​ ​ 10,211 ​ ​ 9,078 ​ ​ 20,124 ​ ​ 15,377 Change in fair value of acquisition-related contingent consideration (income) expense ​ ​ (100) ​ ​ 1,830 ​ ​ 600 ​ ​ 3,006 Acquisition-related expense ​ ​ — ​ ​ 598 ​ ​ 251 ​ ​ 4,289 Stock-based compensation expense ​ ​ 7,173 ​ ​ 6,906 ​ ​ 14,310 ​ ​ 13,758 Adjusted EBITDA ​ $ 7,134 ​ $ 13,652 ​ $ 11,941 ​ $ 19,343 ​ Asset information by segment is not a key measure of performance used by the CODM. Accordingly, the Company has not disclosed asset information by segment.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2020
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation	Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company's interim consolidated financial position for the periods indicated. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results to be expected for the year ending December 31, 2020, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K filed on March 2, 2020 (“2019 Form 10-K”). ​ Effective January 1, 2020, in order to facilitate the administration, management, and development of the Company’s business and minimize the burden on the Company’s tax and regulatory reporting obligations, the Company implemented a reorganization pursuant to which all of the Company’s domestic subsidiaries, other than CK Solutions, LLC, merged with and into the Company’s wholly-owned subsidiary CareKinesis, Inc., which had previously changed its legal name on December 20, 2019 to TRHC OpCo, Inc. In the second quarter of 2020, TRHC OpCo, Inc. further changed its name to Tabula Rasa HealthCare Group, Inc. (“TRHC Group”). Following such reorganization, the Company’s only directly owned subsidiary is TRHC Group, which is the parent of CK Solutions, LLC and of three DoseMe foreign subsidiaries. ​ In conjunction with the Company’s reorganization, the Company now operates its business through two segments, CareVention HealthCare and MedWise HealthCare, effective January 1, 2020. Prior comparative periods have been revised to conform with the current period segment presentation. See Note 16 for a discussion of the Company’s reportable segments. ​ Risks Related to the COVID-19 Pandemic On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency caused by a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this Quarterly Report on Form 10-Q. As such, it is uncertain as to the full magnitude of the impact that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and the ramification on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects that the COVID-19 outbreak may have on the Company’s results of operations, financial condition, or liquidity for 2020. However, the Company is dependent on its workforce to sell and deliver its products and services. Developments such as social distancing and shelter-in-place directives could impact the Company’s ability to deploy its workforce effectively. These same developments may affect the operations of the Company’s suppliers and customers, as their own workforces and operations are disrupted by efforts to curtail the spread of this virus. ​ As a result of the ongoing COVID-19 pandemic, the Company has experienced challenges with revenue growth. The pandemic has delayed the closing of contracts across both the Company’s CareVention HealthCare and MedWise HealthCare segments and, in some cases, shifted project timelines to 2021, resulting in fewer new business wins during the second quarter of 2020. Overall census growth for Programs of All-Inclusive Care for the Elderly (“PACE”) has remained below historical levels, which has affected the Company’s CareVention HealthCare segment growth. The Company’s MedWise HealthCare segment has also experienced delays in the timing of implementation and closing of new business. In addition, all major pharmacy tradeshows for the third quarter of 2020 have been cancelled, negatively impacting a key selling season for the Company’s PrescribeWellness business. However, the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which it relies .
Recent Accounting Pronouncements	Recent Accounting Pronouncements ​ In June 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments ​ In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ​ In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement ​ In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ​ In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ).

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ ​ 2020 ​ ​ 2019 ​ ​ 2020 ​ ​ 2019 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 38,930 ​ $ 33,372 ​ $ 76,017 ​ $ 64,354 PACE solutions ​ ​ 11,522 ​ ​ 11,437 ​ ​ 23,093 ​ ​ 22,611 ​ ​ $ 50,452 ​ $ 44,809 ​ $ 99,110 ​ $ 86,965 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 443 ​ $ — ​ $ 443 ​ $ — Medication safety services ​ ​ 15,707 ​ ​ 22,498 ​ $ 30,027 ​ ​ 37,849 Software subscription and services ​ ​ 10,232 ​ ​ 8,948 ​ ​ 20,081 ​ ​ 12,400 ​ ​ $ 26,382 ​ $ 31,446 ​ $ 50,551 ​ $ 50,249 Total revenue ​ $ 76,834 ​ $ 76,255 ​ $ 149,661 ​ $ 137,214
Schedule of contract assets and contract liabilities from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2020 2019 Contract assets ​ $ 3,595 ​ $ 6,165 Contract liabilities ​ ​ 6,719 ​ ​ 4,930
Schedule of significant changes in the contract assets and the contract liabilities balances	​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2020 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 6,165 Decreases due to cash received ​ ​ (4,147) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 394 Increases, net of reclassifications to receivables ​ ​ 1,183 Contract assets, end of period ​ $ 3,595 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 4,930 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (3,614) Increases due to cash received, excluding amounts recognized as revenue during the period ​ ​ 5,403 Contract liabilities, end of period ​ $ 6,719

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Net (Loss) Income per Share
Schedule of calculation of basic and diluted net (loss) income per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ 2020 ​ 2019 ​ 2020 ​ 2019 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (14,310) ​ $ (6,529) ​ $ (28,747) ​ $ (17,508) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 21,556,646 ​ ​ 20,482,032 ​ ​ 21,465,772 ​ ​ 20,433,564 Net loss per share, basic and diluted ​ $ (0.66) ​ $ (0.32) ​ $ (1.34) ​ $ (0.86)
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2020 2019 Stock options to purchase common stock ​ 2,498,663 ​ 2,948,279 Unvested restricted stock ​ 1,322,064 ​ 1,445,817 Common stock warrants ​ 4,646,393 ​ 4,646,393 Contingently issuable shares ​ 58,409 ​ 5,000 ​ ​ 8,525,529 ​ 9,045,489

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2020
Acquisitions
Schedule of proforma results	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2019 ​ 2019 Revenue ​ $ 76,255 ​ $ 142,961 Net loss ​ ​ (6,395) ​ ​ (18,104)

Software Development Costs (Tab

Software Development Costs (Tables)	6 Months Ended
	Jun. 30, 2020
Software Development Costs
Schedule of capitalized software costs	​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Software development costs $ 38,607 ​ $ 29,714 Less: accumulated amortization ​ (15,185) ​ ​ (11,213) Software development costs, net $ 23,422 ​ $ 18,501 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 2,148 ​ $ 3,294

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 3.5 ​ $ 11,255 ​ $ (4,577) ​ $ 6,678 Client relationships ​ 12.2 ​ ​ 128,169 ​ ​ (26,528) ​ ​ 101,641 Non-competition agreements ​ 5.0 ​ ​ 6,602 ​ ​ (3,302) ​ ​ 3,300 Developed technology ​ 8.0 ​ ​ 68,593 ​ ​ (20,398) ​ ​ 48,195 Patient database ​ 5.0 ​ ​ 21,700 ​ ​ (5,787) ​ ​ 15,913 Domain name ​ 10.0 ​ ​ 59 ​ ​ (18) ​ ​ 41 Total intangible assets ​ ​ ​ $ 236,378 ​ $ (60,610) ​ $ 175,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 7.1 ​ $ 11,255 ​ $ (3,845) ​ $ 7,410 Client relationships ​ 12.2 ​ ​ 128,169 ​ ​ (20,977) ​ ​ 107,192 Non-competition agreements ​ 5.0 ​ ​ 6,602 ​ ​ (2,641) ​ ​ 3,961 Developed technology ​ 8.0 ​ ​ 68,593 ​ ​ (15,870) ​ ​ 52,723 Patient database ​ 5.0 ​ ​ 21,700 ​ ​ (3,617) ​ ​ 18,083 Domain name ​ 10.0 ​ ​ 59 ​ ​ (15) ​ ​ 44 Total intangible assets ​ ​ ​ $ 236,378 ​ $ (46,965) ​ $ 189,413
Schedule of estimated amortization expense	​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2020 (July 1 - December 31) $ 16,584 2021 ​ ​ 26,972 2022 ​ ​ 25,646 2023 ​ ​ 24,436 2024 ​ ​ 17,433 2025 ​ ​ 11,565 Thereafter ​ ​ 53,132 Total estimated amortization expense ​ $ 175,768

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Employee related expenses ​ $ 9,122 ​ $ 12,582 Contract liability ​ ​ 6,234 ​ ​ 4,857 Client funds obligations* ​ ​ 3,132 ​ ​ 4,106 Contract labor ​ ​ 2,143 ​ ​ 329 Interest ​ ​ 2,133 ​ ​ 2,133 Professional fees ​ ​ 247 ​ ​ 337 Royalties expense ​ ​ 180 ​ ​ 17 Non-income taxes payable ​ ​ 1,043 ​ ​ 898 Other expenses ​ ​ 2,710 ​ ​ 1,647 Total accrued expenses and other liabilities ​ $ 26,944 ​ $ 26,906

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Lines of Credit and Long-Term Debt
Schedule of long-term debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2020 December 31, 2019 Convertible senior subordinated notes ​ $ 325,000 ​ $ 325,000 Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (92,342) ​ ​ (98,709) Convertible senior subordinated notes, net ​ ​ 232,658 ​ ​ 226,291 Finance leases ​ ​ 8 ​ ​ 128 Total long-term debt and finance leases, net ​ ​ 232,666 ​ ​ 226,419 Less current portion, net ​ ​ (8) ​ ​ (125) Total long-term debt and finance leases, less current portion, net ​ $ 232,658 ​ $ 226,294

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Stock-Based Compensation
Summary of restricted stock award activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2019 ​ 1,213,581 ​ $ 37.69 Granted ​ 428,656 ​ ​ 66.65 Vested ​ (280,995) ​ ​ 45.39 Forfeited ​ (39,178) ​ ​ 55.72 Outstanding at June 30, 2020 ​ 1,322,064 ​ $ 44.91
Schedule of weighted average assumptions for employee grants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, Valuation assumptions: 2020 2019 Expected volatility ​ 56.10 % ​ 69.60 % Expected term (years) ​ 5.25 ​ ​ 6.02 ​ Risk-free interest rate ​ 1.22 % ​ 2.50 % Dividend yield ​ — ​ ​ — ​
Summary of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2019 ​ 2,755,343 ​ $ 25.10 ​ ​ ​ ​ Granted ​ 5,000 ​ ​ 68.10 ​ ​ ​ ​ ​ Exercised ​ (223,980) ​ ​ 11.11 ​ ​ ​ ​ ​ Forfeited ​ (37,700) ​ ​ 48.73 ​ ​ ​ ​ ​ Outstanding at June 30, 2020 ​ 2,498,663 ​ $ 26.08 ​ 6.6 ​ $ 73,296 Options vested and expected to vest at June 30, 2020 ​ 2,498,663 ​ $ 26.08 ​ 6.6 ​ $ 73,296 Exercisable at June 30, 2020 ​ 1,715,578 ​ $ 18.48 ​ 5.9 ​ $ 62,853
Schedule of recorded stock-based compensation expense related to stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2020 2019 2020 2019 Cost of revenue - product ​ $ 193 ​ $ 313 ​ $ 375 ​ $ 622 Cost of revenue - service ​ ​ 839 ​ ​ 994 ​ ​ 1,602 ​ ​ 1,978 Research and development ​ ​ 1,071 ​ ​ 1,806 ​ ​ 2,480 ​ ​ 4,088 Sales and marketing ​ ​ 523 ​ ​ 1,105 ​ ​ 1,051 ​ ​ 2,092 General and administrative ​ ​ 4,547 ​ ​ 2,688 ​ ​ 8,802 ​ ​ 4,978 Total stock-based compensation expense ​ $ 7,173 ​ $ 6,906 ​ $ 14,310 ​ $ 13,758

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Measurements
Schedule of classified liabilities measured at fair value on recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 June 30, 2020 Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related contingent consideration - long-term ​ $ — ​ $ — ​ $ 11,400 ​ $ 11,400 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurement ​ ​ at Reporting Date Using ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance as of ​ Level 1 Level 2 Level 3 December 31, 2019 Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related contingent consideration - long-term ​ $ — ​ $ — ​ $ 10,800 ​ $ 10,800
Schedule of reconciliation of liability measured at fair value on recurring basis using significant unobservable inputs (Level 3)	​ ​ ​ ​ ​ Balance at December 31, 2019 $ 10,800 Adjustments to fair value measurement ​ ​ 600 Balance at June 30, 2020 ​ $ 11,400
Schedule of carrying value and fair value of financial instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 232,658 ​ $ 332,111

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting
Schedule of reportable operating segment information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ MedWise HealthCare ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 38,930 ​ $ 443 ​ $ 39,373 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 11,522 ​ ​ — ​ ​ 11,522 Medication safety services ​ ​ — ​ ​ 15,707 ​ ​ 15,707 Software subscription and services ​ ​ — ​ ​ 10,232 ​ ​ 10,232 Total service revenue ​ ​ 11,522 ​ ​ 25,939 ​ ​ 37,461 Total revenue ​ $ 50,452 ​ $ 26,382 ​ $ 76,834 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 33,372 ​ $ — ​ $ 33,372 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 11,437 ​ ​ — ​ ​ 11,437 Medication safety services ​ ​ — ​ ​ 22,498 ​ ​ 22,498 Software subscription and services ​ ​ — ​ ​ 8,948 ​ ​ 8,948 Total service revenue ​ ​ 11,437 ​ ​ 31,446 ​ ​ 42,883 Total revenue ​ $ 44,809 ​ $ 31,446 ​ $ 76,255 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 76,017 ​ $ 443 ​ $ 76,460 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 23,093 ​ ​ — ​ ​ 23,093 Medication safety services ​ ​ — ​ ​ 30,027 ​ ​ 30,027 Software subscription and services ​ ​ — ​ ​ 20,081 ​ ​ 20,081 Total service revenue ​ ​ 23,093 ​ ​ 50,108 ​ ​ 73,201 Total revenue ​ $ 99,110 ​ $ 50,551 ​ $ 149,661 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 64,354 ​ $ — ​ $ 64,354 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 22,611 ​ ​ — ​ ​ 22,611 Medication safety services ​ ​ — ​ ​ 37,849 ​ ​ 37,849 Software subscription and services ​ ​ — ​ ​ 12,400 ​ ​ 12,400 Total service revenue ​ ​ 22,611 ​ ​ 50,249 ​ ​ 72,860 Total revenue ​ $ 86,965 ​ $ 50,249 ​ $ 137,214 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ MedWise HealthCare ​ Shared Services ​ Consolidated Adjusted EBITDA (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 12,077 ​ $ 4,697 ​ $ (9,640) ​ $ 7,134 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 11,466 ​ $ 9,059 ​ $ (6,873) ​ $ 13,652 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 23,825 ​ $ 7,528 ​ $ (19,412) ​ $ 11,941 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 22,086 ​ $ 10,707 ​ $ (13,450) ​ $ 19,343 ​
Schedule of reconciliation of the segments? total Adjusted EBITDA to net loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2020 2019 2020 2019 Reconciliation of net loss to Adjusted EBITDA ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (14,310) ​ $ (6,529) ​ $ (28,747) ​ $ (17,508) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 4,668 ​ ​ 4,308 ​ ​ 9,278 ​ ​ 7,001 Income tax benefit ​ ​ (508) ​ ​ (2,539) ​ ​ (3,875) ​ ​ (6,580) Depreciation and amortization ​ ​ 10,211 ​ ​ 9,078 ​ ​ 20,124 ​ ​ 15,377 Change in fair value of acquisition-related contingent consideration (income) expense ​ ​ (100) ​ ​ 1,830 ​ ​ 600 ​ ​ 3,006 Acquisition-related expense ​ ​ — ​ ​ 598 ​ ​ 251 ​ ​ 4,289 Stock-based compensation expense ​ ​ 7,173 ​ ​ 6,906 ​ ​ 14,310 ​ ​ 13,758 Adjusted EBITDA ​ $ 7,134 ​ $ 13,652 ​ $ 11,941 ​ $ 19,343

Nature of Business (Details)

Nature of Business (Details) - Minimum individual in Thousands, $ in Billions	6 Months Ended	12 Months Ended
	Jun. 30, 2020customer	Dec. 31, 2018USD ($)individual
Nature of Business
Estimated U.S. annual cost for adverse drug events | $		$ 528
Estimated annual deaths in U.S. due to adverse drug events | individual		275
Health plans
Nature of Business
Number of organizations served	350
Pharmacies
Nature of Business
Number of organizations served	15,000
At-risk provider-based groups
Nature of Business
Number of organizations served	100

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Basis of Presentation (Details)	6 Months Ended
	Jun. 30, 2020segment
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Number of operating segment	2

Revenue - General (Details)

Revenue - General (Details)	6 Months Ended
	Jun. 30, 2020
Minimum
Contract with customer
Contract term	1 year
Termination notice period	0 days
Maximum
Contract with customer
Contract term	5 years
Termination notice period	180 days

Revenue - Disaggregation (Detai

Revenue - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of revenue
Total revenue	$ 76,834	$ 76,255	$ 149,661	$ 137,214
Product
Disaggregation of revenue
Total revenue	39,373	33,372	76,460	64,354
Service
Disaggregation of revenue
Total revenue	37,461	42,883	73,201	72,860
PACE solutions
Disaggregation of revenue
Total revenue	11,522	11,437	23,093	22,611
Medication safety services
Disaggregation of revenue
Total revenue	15,707	22,498	30,027	37,849
Software Subscription and Services [Member]
Disaggregation of revenue
Total revenue	10,232	8,948	20,081	12,400
MedWise HealthCare
Disaggregation of revenue
Total revenue	26,382	31,446	50,551	50,249
MedWise HealthCare | Product
Disaggregation of revenue
Total revenue	443		443
MedWise HealthCare | Service
Disaggregation of revenue
Total revenue	25,939	31,446	50,108	50,249
MedWise HealthCare | Medication safety services
Disaggregation of revenue
Total revenue	15,707	22,498	30,027	37,849
MedWise HealthCare | Software Subscription and Services [Member]
Disaggregation of revenue
Total revenue	10,232	8,948	20,081	12,400
CareVention HealthCare
Disaggregation of revenue
Total revenue	50,452	44,809	99,110	86,965
CareVention HealthCare | Product
Disaggregation of revenue
Total revenue	38,930	33,372	76,017	64,354
CareVention HealthCare | PACE product revenue
Disaggregation of revenue
Total revenue	38,930	33,372	76,017	64,354
CareVention HealthCare | Service
Disaggregation of revenue
Total revenue	11,522	11,437	23,093	22,611
CareVention HealthCare | PACE solutions
Disaggregation of revenue
Total revenue	$ 11,522	$ 11,437	$ 23,093	$ 22,611

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Contract Balances
Contract assets	$ 3,595	$ 6,165
Contract liabilities	$ 6,719	$ 4,930	$ 1,733

Revenue - Change in contract ba

Revenue - Change in contract balances (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Contract assets:
Contract assets, beginning of period	$ 6,165
Decreases due to cash received	(4,147)
Changes to the contract assets at the beginning of the period as a result of changes in estimates	394
Increases, net of reclassifications to receivables	1,183
Contract assets, end of period	3,595
Contract liabilities:
Contract liabilities, beginning of period	4,930	$ 1,733
Revenue recognized that was included in the contract liabilities balance at the beginning of the period	(3,614)	$ (1,408)
Increases due to cash received, excluding amounts recognized as revenue during the year	5,403
Contract liabilities, end of period	$ 6,719

Net Loss per Share - EPS (Detai

Net Loss per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator (basic and diluted):
Net loss, basic	$ (14,310)	$ (6,529)	$ (28,747)	$ (17,508)
Net loss, diluted	$ (14,310)	$ (6,529)	$ (28,747)	$ (17,508)
Denominator (basic and diluted):
Weighted average common shares outstanding, basic and diluted (in shares)	21,556,646	20,482,032	21,465,772	20,433,564
Net loss per share, basic and diluted (in dollars per share)	$ (0.66)	$ (0.32)	$ (1.34)	$ (0.86)

Net (Loss) Income per Share - A

Net (Loss) Income per Share - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	8,525,529	9,045,489
Stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	2,498,663	2,948,279
Restricted stock
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	1,322,064	1,445,817
Common stock warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	4,646,393	4,646,393
Contingently issuable shares
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	58,409	5,000

Acquisitions - Prescribe Wellne

Acquisitions - Prescribe Wellness (Details) $ in Thousands	Mar. 05, 2019USD ($)company	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Acquisition
Total revenue		$ 76,834		$ 76,255		$ 149,661	$ 137,214
Net loss		(14,310)	$ (14,437)	(6,529)	$ (10,979)	(28,747)	(17,508)
Amortization expense		6,823		7,084		13,645	11,751
Service
Acquisition
Total revenue		$ 37,461		42,883		$ 73,201	72,860
Prescribe Wellness
Acquisition
Cash consideration	$ 150,000
Total revenue				$ 7,919			$ 10,110
Revenue from Contract with Customer, Product and Service				us-gaap:ServiceMember			us-gaap:ServiceMember
Net loss				$ (2,925)			$ (3,796)
Amortization expense				3,277			4,151
Prescribe Wellness | Service
Acquisition
Reduction to revenue recorded due to purchase accounting effects of recording deferred revenue at fair value				$ (544)			$ (747)
Prescribe Wellness | Minimum
Acquisition
Number of pharmacies with which acquiree facilitates collaboration | company	12,000

Acquisitions - DoseMe (Details)

Acquisitions - DoseMe (Details) - USD ($) $ in Thousands	Jan. 02, 2019	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Acquisition
Total revenue		$ 76,834			$ 76,255		$ 149,661	$ 137,214
Net loss		(14,310)	$ (14,437)		(6,529)	$ (10,979)	(28,747)	(17,508)
Amortization expense		6,823			7,084		13,645	11,751
DoseMe
Acquisition
Cash consideration	$ 10,000
Issuance of common stock (in shares)	149,053
Cash payment for acquisition-related contingent consideration				$ 8,750
Total revenue					$ 72			$ 138
Revenue from Contract with Customer, Product and Service					us-gaap:ServiceMember			us-gaap:ServiceMember
Net loss					$ (769)			$ (1,995)
Amortization expense					579			1,141
Service
Acquisition
Total revenue		$ 37,461			$ 42,883		$ 73,201	$ 72,860

Acquisitions - Pro forma (unaud

Acquisitions - Pro forma (unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Acquisitions
Revenue	$ 76,255	$ 142,961
Net loss	$ (6,395)	$ (18,104)

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property and Equipment
Property and equipment, net	$ 15,531		$ 15,531		$ 15,798
Depreciation and amortization	10,211	$ 9,078	20,124	$ 15,377
Property and equipment
Property and Equipment
Accumulated depreciation	15,701		15,701		$ 13,728
Depreciation and amortization	$ 1,234	$ 1,089	$ 2,502	$ 2,097

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Software development costs	$ 38,607		$ 38,607		$ 29,714
Less: accumulated amortization	(15,185)		(15,185)		(11,213)
Software development costs, net	23,422		23,422		18,501
Capitalized software development costs included above not yet subject to amortization	2,148		2,148		$ 3,294
Depreciation and amortization	10,211	$ 9,078	20,124	$ 15,377
Software Development Costs
Depreciation and amortization	$ 2,154	$ 905	$ 3,977	$ 1,529

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Goodwill and related changes
Goodwill	$ 150,760	$ 150,760

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Intangible Assets
Gross Value	$ 236,378		$ 236,378		$ 236,378
Accumulated Amortization	(60,610)		(60,610)		(46,965)
Intangible Assets, net	175,768		175,768		$ 189,413
Amortization expense	6,823	$ 7,084	$ 13,645	$ 11,751
Trade name
Intangible Assets
Weighted Average Amortization Period			3 years 6 months		7 years 1 month 6 days
Gross Value	11,255		$ 11,255		$ 11,255
Accumulated Amortization	(4,577)		(4,577)		(3,845)
Intangible Assets, net	6,678		$ 6,678		$ 7,410
Client relationships
Intangible Assets
Weighted Average Amortization Period			12 years 2 months 12 days		12 years 2 months 12 days
Gross Value	128,169		$ 128,169		$ 128,169
Accumulated Amortization	(26,528)		(26,528)		(20,977)
Intangible Assets, net	101,641		$ 101,641		$ 107,192
Non-competition agreement
Intangible Assets
Weighted Average Amortization Period			5 years		5 years
Gross Value	6,602		$ 6,602		$ 6,602
Accumulated Amortization	(3,302)		(3,302)		(2,641)
Intangible Assets, net	3,300		$ 3,300		$ 3,961
Developed technology
Intangible Assets
Weighted Average Amortization Period			8 years		8 years
Gross Value	68,593		$ 68,593		$ 68,593
Accumulated Amortization	(20,398)		(20,398)		(15,870)
Intangible Assets, net	48,195		$ 48,195		$ 52,723
Patient database
Intangible Assets
Weighted Average Amortization Period			5 years		5 years
Gross Value	21,700		$ 21,700		$ 21,700
Accumulated Amortization	(5,787)		(5,787)		(3,617)
Intangible Assets, net	15,913		$ 15,913		$ 18,083
Domain name
Intangible Assets
Weighted Average Amortization Period			10 years		10 years
Gross Value	59		$ 59		$ 59
Accumulated Amortization	(18)		(18)		(15)
Intangible Assets, net	$ 41		$ 41		$ 44

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Estimated amortization expense
2020 (July 1 - December 31)	$ 16,584
2021	26,972
2022	25,646
2023	24,436
2024	17,433
2025	11,565
Thereafter	53,132
Total estimated amortization expense	$ 175,768	$ 189,413

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accrued Expenses and Other Liabilities
Employee related expenses	$ 9,122	$ 12,582
Contract liability	6,234	4,857
Client funds obligations	3,132	4,106
Contract labor	2,143	329
Interest	2,133	2,133
Professional fees	247	337
Royalties expense	180	17
Non-income taxes payable	1,043	898
Other expenses	2,710	1,647
Total accrued expenses and other liabilities	$ 26,944	$ 26,906

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit (Details) - 2015 Line of Credit - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Sep. 06, 2017
Lines of Credit
Maximum borrowing capacity						$ 60,000
Sublimit of loan						$ 1,000
Letter of credit outstanding	$ 200		$ 200
Aggregate borrowings outstanding	0		0		$ 0
Amounts available for borrowings	$ 59,800		$ 59,800
Interest rate (as a percent)	5.58%	5.58%	5.58%	5.58%
Interest expense	$ 0	$ 0	$ 0	$ 351
Aggregate borrowings outstanding during the period	0	0	0
Deferred financing costs	793		793
Amortization of deferred financing costs to interest expense	99	$ 61	199	$ 109
Deferred financing costs	$ 67		$ 67		$ 266
Prime Rate
Lines of Credit
Floor rate (as a percent)			3.50%
Minimum | Prime Rate
Lines of Credit
Spread on variable rate (as a percent)			(0.25%)
Maximum | Prime Rate
Lines of Credit
Spread on variable rate (as a percent)			0.25%

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Convertible Senior Subordinated Notes (Details) $ / shares in Units, $ in Thousands	Feb. 12, 2019USD ($)$ / shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)D	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Lines of Credit and Long-Term Debt
Cash paid for interest				$ 2,846	$ 364
Long term debt, net		$ 232,658		232,658		$ 226,291
Accrued interest payable		2,133		2,133		$ 2,133
Convertible Senior Subordinated Notes
Lines of Credit and Long-Term Debt
Aggregate borrowings	$ 325,000	$ 325,000		$ 325,000
Interest rate (as a percent)	1.75%	1.75%		1.75%
Initial conversion rate	0.0142966
Initial conversion price | $ / shares	$ 69.95
Carrying amount of the equity component representing the conversion option	$ 102,900
Deferred tax effect	$ 25,884
Effective interest rate	8.05%
Debt issuance costs	$ 9,372
Issuance costs attributable to the liability component	$ 6,405
Interest expense		$ 4,638	$ 4,389	$ 9,211	6,659
Increase in accrued interest		1,423	1,422	2,844	2,164
Non-cash accretion of the debt discounts		3,215	$ 2,967	6,367	$ 4,494
Long term debt, net		232,658		232,658
Accrued interest payable		2,133		$ 2,133
Debt Conversion Scenario One | Convertible Senior Subordinated Notes
Lines of Credit and Long-Term Debt
Trading days | D				20
Consecutive trading days | D				30
Stock price trigger percentage (as a percent)				130.00%
Debt Conversion Scenario Two | Convertible Senior Subordinated Notes
Lines of Credit and Long-Term Debt
Trading days | D				5
Consecutive trading days | D				5
Principal amount		$ 1		$ 1
Stock price trigger percentage (as a percent)				98.00%

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Convertible Note Hedge and Warrant Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 12, 2019	Jun. 30, 2019
Lines of Credit and Long-Term Debt
Proceeds from Issuance of Warrants		$ 65,910
Convertible note warrant
Lines of Credit and Long-Term Debt
Option to purchase	4,646,393
Exercise price (in dollars per share)	$ 105.58
Proceeds from Issuance of Warrants	$ 65,910
Note hedges
Lines of Credit and Long-Term Debt
Option to purchase	4,646,393
Exercise price (in dollars per share)	$ 69.95
Premiums paid for the note hedges	$ 101,660

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Long-term debt (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Capital Lease Obligations
Long term debt, gross	$ 325,000	$ 325,000
Unamortized discount, including debt issuance costs, on convertible senior subordinated notes	(92,342)	(98,709)
Long term debt, net	232,658	226,291
Finance leases	8	128
Total long-term debt and finance leases, net	232,666	226,419
Less current portion, net	(8)	(125)
Long-term debt and finance leases, net	$ 232,658	$ 226,294

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Taxes
Income tax benefit	$ (508)	$ (2,539)	$ (3,875)	$ (6,580)
Effective tax rate (as a percent)			11.90%	27.30%
Tax benefit based on estimated effective tax rate for the full year				$ 3,884
Income tax benefit, Tax windfall				$ (2,186)

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - Convertible note warrant - $ / shares	6 Months Ended
	Jun. 30, 2020	Feb. 12, 2019
Warrants
Number of shares called by warrants issued		4,646,393
Exercise Price (in dollars per share)		$ 105.58
Shares issued from exercise of warrants	0

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - 2016 Plan - shares	Jan. 02, 2019	Sep. 30, 2016	Jun. 30, 2020
Stock-Based Compensation
Automatic increase on share reserve (as a percent)		5.00%
Additional shares authorized	1,116,065
Available for future grant (in shares)			1,128,118

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Weighted average grant date fair value
Total stock-based compensation expense (in dollars)	$ 7,173	$ 6,906	$ 14,310	$ 13,758
Restricted stock
Number of shares
Outstanding at beginning of period (in shares)			1,213,581
Granted (in shares)			428,656
Vested (in shares)			(280,995)
Forfeited (in shares)			(39,178)
Outstanding at end of period (in shares)	1,322,064		1,322,064
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share)			$ 37.69
Granted (in dollars per share)			66.65
Vested (in dollars per share)			45.39
Forfeited (in dollars per share)			55.72
Outstanding at end of period (in dollars per share	$ 44.91		$ 44.91
Total stock-based compensation expense (in dollars)	$ 4,809	$ 3,361	$ 8,948	$ 6,086
Unrecognized compensation expense (in dollars)	$ 47,428		$ 47,428
Weighted average period expected to be recognized			2 years 10 months 24 days

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Equity Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	May 04, 2020	Aug. 06, 2018	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stock-Based Compensation
Stock- based stock awards expense			$ 7,173		$ 6,906	$ 14,310	$ 13,758
Performance-Based Equity Awards
Stock-Based Compensation
Granted (in shares)		50,000		5,000
Weighted average grant-date fair value (in dollars per share)		$ 61.85
Stock- based stock awards expense					$ 399		$ 1,314
Unrecognized compensation expense (in dollars)								$ 0
Performance-Based Equity Awards | Employee
Stock-Based Compensation
Granted (in shares)	10,686
Weighted average grant-date fair value (in dollars per share)	$ 56.14
Stock- based stock awards expense			0			0
Unrecognized compensation expense (in dollars)			$ 600			$ 600

Stock-Based Compensation - Othe

Stock-Based Compensation - Other Stock Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-Based Compensation
Total stock-based compensation expense (in dollars)	$ 7,173		$ 6,906	$ 14,310	$ 13,758
Other stock awards
Stock-Based Compensation
Granted (in shares)		9,386			19,648
Weighted average grant-date fair value (in dollars per share)		$ 52.29			$ 53.03
Total stock-based compensation expense (in dollars)			$ 504	$ 491	$ 1,042

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-Based Compensation
Total stock-based compensation expense (in dollars)	$ 7,173	$ 6,906	$ 14,310	$ 13,758
Stock options
Stock-Based Compensation
Total stock-based compensation expense (in dollars)	$ 2,364	$ 2,642	$ 4,871	$ 5,316
Valuation assumptions:
Expected volatility (as a percent)			56.10%	69.60%
Expected term (years)			5 years 3 months	6 years 7 days
Risk-free interest rate (as a percent)			1.22%	2.50%
Weighted average grant-date fair value (in dollars per share)			$ 33.78	$ 34.94

Stock-Based Compensation - Op_2

Stock-Based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Number of shares
Outstanding at beginning of period (in shares)	2,755,343
Granted (in shares)	5,000
Exercised (in shares)	(223,980)
Forfeited (in shares)	(37,700)
Outstanding at end of the period (in shares)	2,498,663
Options vested and expected to vest at end of the period (in shares)	2,498,663
Exercisable at end of period (in shares)	1,715,578
Weighted average exercise price
Outstanding at beginning of period (in dollars per share)	$ 25.10
Granted (in dollars per share)	68.10
Exercised (in dollars per share)	11.11
Forfeited (in dollars per share)	48.73
Outstanding at end of period (in dollars per share)	26.08
Options vested and expected to vest at end of period (in dollars per share)	26.08
Exercisable at end of period (in dollars per share)	$ 18.48
Weighted average remaining contractual term
Outstanding	6 years 7 months 6 days
Options vested and expected to vest at of the period	6 years 7 months 6 days
Exercisable	5 years 10 months 24 days
Aggregate intrinsic value
Outstanding (in dollars)	$ 73,296
Options vested and expected to vest at end of period (in dollars)	73,296
Exercisable (in dollars)	62,853
Additional disclosures
Intrinsic value of options exercised (in dollars)	9,656	$ 5,959
Proceeds from stock options exercised (in dollars)	2,312	$ 1,536
Stock options
Additional disclosures
Total unrecognized compensation cost (in dollars)	$ 19,044
Weighted average period expected to be recognized	2 years 3 months 18 days

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	$ 7,173	$ 6,906	$ 14,310	$ 13,758
Cost of revenue - product
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	193	313	375	622
Cost of revenue - service
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	839	994	1,602	1,978
Research and development
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	1,071	1,806	2,480	4,088
Sales and marketing
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	523	1,105	1,051	2,092
General and administrative
Stock-based compensation expense
Total stock-based compensation expense (in dollars)	$ 4,547	$ 2,688	$ 8,802	$ 4,978

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities (Details) - Recurring - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Measurements
Acquisition-related contingent consideration - long-term	$ 11,400	$ 10,800
Level 3
Fair Value Measurements
Acquisition-related contingent consideration - long-term	$ 11,400	$ 10,800

Fair Value Measurements - Conti

Fair Value Measurements - Contingent consideration (Details) - USD ($) $ in Thousands	Jan. 02, 2019	Oct. 19, 2018	Jun. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Change in fair value
Change in fair value of acquisition-related contingent consideration (income) expense			$ (100)		$ 1,830	$ 600	$ 3,006
Cognify, Inc
Change in fair value
Change in fair value of acquisition-related contingent consideration (income) expense			(100)		$ 1,500	600	$ 2,400
Contingent consideration liability			$ 11,400			$ 11,400		$ 10,800
Cognify, Inc | Maximum
Change in fair value
Estimated fair value of contingent consideration		$ 14,000
DoseMe
Change in fair value
Cash payment for acquisition-related contingent consideration				$ 8,750
Issuance of common stock (in shares)	149,053

Fair Value Measurements - Con_2

Fair Value Measurements - Contingent consideration rollforward (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Change in fair value using significant unobservable inputs (Level 3):
Balance at beginning of period	$ 10,800
Adjustments to fair value measurement	600
Balance at end of period	$ 11,400

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Feb. 12, 2019
Fair Value Measurements
Amount before unaccreted debt discount and unamortized debt issuance costs	$ 325,000	$ 325,000
Convertible Senior Subordinated Notes
Fair Value Measurements
Interest rate (as a percent)	1.75%		1.75%
Face value	$ 325,000		$ 325,000
Amount before unaccreted debt discount and unamortized debt issuance costs	325,000
Convertible Senior Subordinated Notes | Carrying Value
Fair Value Measurements
Debt instrument	232,658
Convertible Senior Subordinated Notes | Fair Value
Fair Value Measurements
Debt instrument	$ 332,111

Commitments and Contingencies -

Commitments and Contingencies - Vendor Purchase Agreements (Details) - USD ($) $ in Thousands	Jan. 01, 2020	Mar. 29, 2019	Jun. 30, 2020	Dec. 31, 2019
AmerisourceBergen and Thrifty Drug Stores, Inc.
Purchase Agreements
Amount due as a result of prescription drug purchases			$ 2,399	$ 2,465
Thrifty Drug Stores, Inc.
Purchase Agreements
Purchase obligation (as a percent)		98.00%
Data aggregation partner
Purchase Agreements
Monthly minimum purchase obligation	$ 30
Purchase obligation period	3 years

Segment Reporting - Revenue and

Segment Reporting - Revenue and EBITDA (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)segment	Jun. 30, 2019USD ($)
Segment Reporting
Number of operating segment | segment			2
Number of reportable segment | segment			2
Total revenue	$ 76,834	$ 76,255	$ 149,661	$ 137,214
Adjusted EBITDA (loss)	7,134	13,652	11,941	19,343
Shared Services
Segment Reporting
Adjusted EBITDA (loss)	(9,640)	(6,873)	(19,412)	(13,450)
Product
Segment Reporting
Total revenue	39,373	33,372	76,460	64,354
Service
Segment Reporting
Total revenue	37,461	42,883	73,201	72,860
PACE solutions
Segment Reporting
Total revenue	11,522	11,437	23,093	22,611
Medication safety services
Segment Reporting
Total revenue	15,707	22,498	30,027	37,849
Software Subscription and Services [Member]
Segment Reporting
Total revenue	10,232	8,948	20,081	12,400
CareVention HealthCare
Segment Reporting
Total revenue	50,452	44,809	99,110	86,965
CareVention HealthCare | Operating Segments
Segment Reporting
Adjusted EBITDA (loss)	12,077	11,466	23,825	22,086
CareVention HealthCare | Product
Segment Reporting
Total revenue	38,930	33,372	76,017	64,354
CareVention HealthCare | Service
Segment Reporting
Total revenue	11,522	11,437	23,093	22,611
CareVention HealthCare | PACE solutions
Segment Reporting
Total revenue	11,522	11,437	23,093	22,611
MedWise HealthCare
Segment Reporting
Total revenue	26,382	31,446	50,551	50,249
MedWise HealthCare | Operating Segments
Segment Reporting
Adjusted EBITDA (loss)	4,697	9,059	7,528	10,707
MedWise HealthCare | Product
Segment Reporting
Total revenue	443		443
MedWise HealthCare | Service
Segment Reporting
Total revenue	25,939	31,446	50,108	50,249
MedWise HealthCare | Medication safety services
Segment Reporting
Total revenue	15,707	22,498	30,027	37,849
MedWise HealthCare | Software Subscription and Services [Member]
Segment Reporting
Total revenue	$ 10,232	$ 8,948	$ 20,081	$ 12,400

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of net loss to Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Reconciliation of net loss to Adjusted EBITDA
Net loss	$ (14,310)	$ (14,437)	$ (6,529)	$ (10,979)	$ (28,747)	$ (17,508)
Interest expense, net	4,668		4,308		9,278	7,001
Income tax benefit	(508)		(2,539)		(3,875)	(6,580)
Depreciation and amortization	10,211		9,078		20,124	15,377
Change in fair value of acquisition-related contingent consideration (income) expense	(100)		1,830		600	3,006
Acquisition-related expense			598		251	4,289
Stock-based compensation expense	7,173		6,906		14,310	13,758
Adjusted EBITDA	$ 7,134		$ 13,652		$ 11,941	$ 19,343